Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Operating Leases of $198.5 million for Q1 2026, down 3.39% year-over-year from $205.5 million in Q1 2025, and little changed quarter-over-quarter from $199.4 million in Q4 2025.
Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2026) Analysis & Trends
Sarepta Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $198.5 million for Q1 2026.
- In Q1 2026, Operating Leases fell 3.39% year-over-year to $198.5 million; the TTM figure through Mar 2026 stood at $198.5 million (down 3.39% YoY), while the FY2025 annual figure was $199.4 million, up 3.59% from the prior year.
- Operating Leases for Q1 2026 stood at $198.5 million, roughly flat from $199.4 million in the prior quarter.
- The five-year high for Operating Leases was $215.0 million in Q3 2025, with the low at $35.2 million in Q3 2022.
- The 5-year median for Operating Leases is $141.0 million (2023), against an average of $135.8 million.
- The sharpest annual moves came in 2022 and 2023: Operating Leases sank 44.46% in 2022, then jumped 282.5% in 2023.
- Sarepta Therapeutics' Operating Leases stood at $57.6 million in 2022, then soared by 144.82% to $141.0 million in 2023, then soared by 36.54% to $192.5 million in 2024, then rose by 3.59% to $199.4 million in 2025, then retreated by 0.44% to $198.5 million in 2026.
- Business Quant data shows SRPT's Operating Leases at $198.5 million in Q1 2026, $199.4 million in Q4 2025, and $215.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 198.23 Mn |
| Mar 31, 2026 | 198.51 Mn |
| Dec 31, 2025 | 199.38 Mn |
| Sep 30, 2025 | 215.04 Mn |
| Jun 30, 2025 | 214.42 Mn |
| Mar 31, 2025 | 205.46 Mn |
| Dec 31, 2024 | 192.47 Mn |
| Sep 30, 2024 | 170.01 Mn |
| Jun 30, 2024 | 143.60 Mn |
| Mar 31, 2024 | 140.10 Mn |
| Dec 31, 2023 | 140.97 Mn |
| Sep 30, 2023 | 134.75 Mn |
| Jun 30, 2023 | 129.17 Mn |
| Mar 31, 2023 | 53.93 Mn |
| Dec 31, 2022 | 57.58 Mn |
| Sep 30, 2022 | 35.23 Mn |
| Jun 30, 2022 | 39.37 Mn |
| Mar 31, 2022 | 38.62 Mn |
| Dec 31, 2021 | 41.51 Mn |
| Sep 30, 2021 | 63.43 Mn |